期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

以血小板明显增多为首发表现的慢性髓细胞白血病2例报道并文献复习 被引量：2

原文传递
导出
摘要 例1，男，70岁，以“健康体检时发现血小板明显升高1周”于2007年4月12日入院。无发热、盗汗、消瘦等。体格检查：体温36．8℃，浅表淋巴结无肿大，心脏、肺部未见异常，肝脏、脾脏肋缘下未触及。辅助检查：（1）血常规示白细胞12．1×10^9／L，血红蛋白134g／L，血小板1848×10^9／L，白细胞分类正常。（2）肝脏、肾脏功能正常。中性粒细胞碱性磷酸酶（neutrophilicalkalinephosphatase，NAP）积分40，阳性率30％。血清铁蛋白及维生素B12：正常。
作者 汤春静 孙伟 任辉 夏珊珊 王毅力
机构地区 威海市立医院血液科
出处 《中华实用诊断与治疗杂志》 2011年第11期1122-1123,共2页 Journal of Chinese Practical Diagnosis and Therapy
关键词 慢性髓细胞白血病 血小板增多 原发性血小板增多症
分类号 R733.7 [医药卫生—肿瘤]
  • 相关文献

参考文献5

  • 1林凤茹,王艳,陈静.bcr-abl基因阳性血小板增多症八例报告——附文献复习[J].中华血液学杂志,2004,25(9):528-531. 被引量：9
  • 2Murphy S, Peterson P, Iland H, et al. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survivaL, and leukemic transition by treatment[J]. Semin Hematol,1997, 34(1):29-39.
  • 3Elaine S, Harris N, Stein H, et al. Pathology and genetics of tumors of haematopietic and lymphoid tissues[M]. Lyon: IARC Press International Agency for Research on Cancer (1ARC) 69008,2001:39-41.
  • 4Vannucchi A M, Guglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms[J] CA Cancer J Clin,2009,59(3):171-191.
  • 5Yokota A, Kimura S, Masuda S, et al. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity[J]. Blood,2007,109 (1) :306-314.

二级参考文献9

  • 1Inokuchi K, Futaki M, Hanawa H, et al. Heterogenous expression of bcr-abl fusion mRNA in a patient with Philadelphia-chromosome-positive actue lymphoblastic leukaemia. Br J Haematol,1997, 97:837-840.
  • 2Zaccaria A, Tura S. A chromosomal abnormality in primary thrombocythemia. N Engl J Med, 1978, 298:1422-1423.
  • 3Fitzgerald PH, McEwan C, Fraser J, et al. A complex Ph1 translocation in a patient with primary thrombocythaemia. Br J Haematol, 1981,47:571-575.
  • 4Verhest A, Monsieur R. Philadelphia chromosome-positive thrombocythemia with leukemic transformation. N Engl J Med,1983,308: 1603.
  • 5Stoll DB, Peterson P, Exten R, et al. Clinical presentation and natural history of patients with essential thrombocythemia and the Philadelphia chromosome. Am J Hematol, 1988,27:77-83.
  • 6Morris CM, Fitzgerald PH, Hollings PE, et al. Essntial thrombocythaemia and the Philadelphia chromosome. Br J Haematol,1988,70:13-19.
  • 7Blickstein D, Aviram A, Luboshitz J, et al. BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocytoperia patients: clinical presentations. Blood,1997,90:2768-2771.
  • 8Satoh A, Miwa H, Daimaru O, et al. Aplastic anaemia associated with a Philadelphia chromosome and monosomy 7 during immunosuppressive theray.Eur J Haematol,2003,71:130-132.
  • 9Bose S,Deininger M,Gora-Tybor J,et al. The presence of typical and atypical BCR-ABLfusion genes inleukocytes of normal individuals:biologic significance and implications forthe as sessment of minimal residual disease.Blood,1998,92:3362-3367.

共引文献8

同被引文献11

  • 1江继发,金凤祥,肖明敏,程文燕.甲磺酸伊马替尼治疗慢性粒细胞性白血病的疗效观察[J].实用诊断与治疗杂志,2007,21(12):942-943. 被引量：8
  • 2Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia= rationale and important changes [-J~. Blood,2009,114(5)=937-951.
  • 3Dusa A, Mouton C, Pecquet C, et al. JAK2 V617F constitutive activation requires JH2 residue F595.. a pseudokinase domain target for specific inhibitors]-J~. PLoS One,2010,5(6) =e11157.
  • 4Wu Z, Zhang X, Xu X, et al. The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome- negative myeloproliferative neoplasms I-J~. J Hemato*t Oncol, 2014,7(48) :1-10. .
  • 5Zhang SP, Li H, Lai RS. Detection of JAK2 V617F mutation increases the diagnosis of myeloproliferative neoplasms E J 1. Oncol Lett,2015,9(2) =735 738.
  • 6Hassan A, Dogara LG, Babadoko AA, et al. Coexistence of JAK2 and BCR ABL mutation in patient with myeloproliferative neoplasmEJ~. Niger MedJ,2015,56(1)=74-76.
  • 7Jekarl DW, Han SB, Kim M, et al. JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/ myeloprofiferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemiaEJ~. Korean J Hematol,2010,45(1) :46-50.
  • 8Ma W, Kantarjian H, Zhang X, et al. JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms E J 1. PLoS One,2010,5(8) :e12165.
  • 9Sun X, Xu Z, Xie L, et al. A novel Janus Kinase 2 mutation involving 14th intron splicing region in a patient with essential thrombocythemia I-J]. Leuk Lymphoma, 2009,50 (12) : 2089- 2091.
  • 10王丹蕾,马保根,张茵,翟亚萍.白血病微小残留病的分子生物学检测[J].中华实用诊断与治疗杂志,2009,23(10):937-939. 被引量：5

引证文献2

中华实用诊断与治疗杂志
2011年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部